跳至主要内容
临床试验/IRCT20190217042737N2
IRCT20190217042737N2已完成2 期

The effect of compound Ma-ol-asal on clinical manifestations and quality of life of chronic obstructive pulmonary disease (COPD) patients

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 76 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
76

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Patients with COPD referring to the lung clinic
  • People who are willing to participate in the study.

排除标准

  • Very severe COPD require hospitalization
  • Underlying illnesses, such as CF, Broncho-pulmonary dysplasia, heart failure, broncho-tracheomalacia, bronchiectasis, pulmonary embolism and sarcoidosis.
  • Taking drugs such as aspirin, beta-blocker and NSAID.
  • Allergic to any of the components of Ma-ol-asal

研究者

发起方
Bagheiat-allah University of Medical Sciences

相似试验